Article

AMO announces expansion of refractive portfolio

AMO today announced the introduction of three new refractive technologies to the European market; the Tecnis 1-piece intraocular lens (IOL), the Tecnis multifocal acrylic IOL and the WhiteStar Signature phaco system.

AMO today announced the introduction of three new refractive technologies to the European market; the Tecnis 1-piece intraocular lens (IOL), the Tecnis multifocal acrylic IOL and the WhiteStar Signature phaco system.

The Tecnis 1-piece IOL combines the reduced spherical aberration properties of all Tecnis lenses with an innovative ProTec 350-degree edge design, which boasts an uninterrupted barrier edge that is designed to minimise cell migration onto the posterior capsule. According to the manufacturers, the 1-piece lens has no interruption at the haptic-optic junction, its frosted edge minimises edge glare and the Tri-Fix design provides three-point fixation for lens stability.

"This new generation one-piece design has responded to the issues associated with existing one-piece IOLs," said Donald R. Nixon, MD in a press statement.

The Tecnis multifocal acrylic IOL, as its name suggests, is the acrylic version of AMO's silicone lens, which has been available for the past three years. According to the firm, the hydrophobic acrylic material helps lower chromatic dispersion for improved vision whilst the wavefront-designed aspheric surface compensates for spherical aberration.

"The new Tecnis multifocal acrylic IOL combines the outstanding visual performance benefits of the Tecnis multifocal optic design with a proven hydrophobic acrylic material that provides unmatched clarity," said Michael Knorz, MD, in a press statement.

The acrylic material of both the Tecnis 1-piece and Tecnis multifocal blocks UV light, whilst transmitting blue light.

Finally, AMO's WhiteStar Signature phacoemulsification system, which was launched in the US earlier this year, is now being made available to European surgeons. This new system combines the proven safety and efficiency of the firm's WhiteStar technology with Fusion Fluidics technology for excellent chamber stability. According to the manufacturers, the system reduces post'occlusion surge by a significant margin, whilst its high flow and vacuum capabilities provides a peristaltic flow of up to 60 cc/min and maximum vacuum of 650 mmHg.

Each of AMO's new technologies will be available in Europe from this month.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.